Low-dose alfacalcidol controls secondary hyperparathyroidism in predialysis chronic kidney disease

Nephron - Clinical Practice

Volumn 114, Issue 4, 2010, Pages

  Reichel, Helmut ^a  

^a Nephrological Center   (Germany)

Author keywords

Alfacalcidol; Calcium; Hyperparathyroidism; Parathyroid hormone; Phosphate; Predialysis

Indexed keywords

ALFACALCIDOL; BONDIOL; CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; COLECALCIFEROL; DIHYDROTACHYSTEROL; PARATHYROID HORMONE; PHOSPHATE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG INTERMITTENT THERAPY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; KIDNEY FUNCTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; REMISSION; SECONDARY HYPERPARATHYROIDISM;

ADULT; AGED; AGED, 80 AND OVER; CALCIUM; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYDROXYCHOLECALCIFEROLS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; YOUNG ADULT;

EID: 74249108843     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000276579     Document Type: Article

References (20)

1. Reichel H, Deibert B, Schmidt-Gayk H, Ritz E: Calcium metabolism in early chronic renal failure. Implications for the pathogenesis of hyperparathyroidism. Nephrol Dial Transplant 1991; 6: 162-169.
2. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218. (Pubitemid 39031360)
3. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa KM, Bommer J, Piera L, Port FK: Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67: 1179-1187. (Pubitemid 41623345)
4. Memmos DE, Eastwood JB, Talner LB, Gower PE, Curtis JR, Phillips ME, Carter GD, Alaghband-Zadeh J, Roberts AP, de Wardener HE: Double-blind trial of oral 1,25- dihydroxy vitamin D 3 versus placebo in asymptomatic hyperparathyroidism in patients receiving maintenance haemodialysis. Br Med J (Clin Res Ed) 1981; 282: 1919-1924.
5. Hamdy NAT, Kanis JA, Beneton MNC, Brown CB, Juttmann JR, Jordans JG, Josse S, Meyrier A, Lins RL, Fairey IT: Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 1995; 310: 358-363.
6. Ritz E, Küster S, Schmidt-Gayk H, Stein G, Scholz C, Kraatz G, Heidland A: Low-dose calcitriol prevents the rise in 1,84-iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicentre trial). Nephrol Dial Transplant 1995; 10: 2228-2234. (Pubitemid 26033434)
7. Baker LR, Abrams L, Roe CJ, Faugere MC, Fanti P, Subayti Y, Malluche HM: 1,25(OH) 2 D 3 administration in moderate renal failure: a prospective double-blind trial. Kidney Int 1989; 35: 661-669. (Pubitemid 19051767)
8. Nordal KP, Dahl E: Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. J Clin Endocrinol Metab 1988; 5: 929-936.
9. Bertoli M, Luisetto G, Ruffati A, Urso M, Romagnoli G: Renal function during calcitriol therapy in chronic renal failure. Clin Nephrol 1990; 33: 98-102. (Pubitemid 20058516)
10. Kimura Y, Nakayama M, Kuriyama S, Watanabe S, Kawaguchi Y, Sakai O: Pharmacokinetics of active vitamins D 3 , 1 alpha-hydroxyvitamin D 3 and 1 alpha, 25-dihydroxyvitamin D 3 in patients on chronic hemodialysis. Clin Nephrol 1991; 35: 71-77.
11. Seino Y, Tanaka H, Yamaoka K, Yabuuchi H: Circulating 1 alpha,25-dihydroxyvitamin D levels after a single dose of 1 alpha,25- dihydroxyvitamin D 3 or 1 alpha-hydroxyvitamin D 3 in normal men. Bone Miner 1987; 2: 479-485.
12. Brandi L, Egfjord M, Olgaard K: Pharmacokinetics of 1,25(OH) 2 D 3 and 1alpha(OH)D 3 in normal and uremic men. Nephrol Dial Transplant 2002; 17: 829-842.
13. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D: Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 71: 1004-1013. (Pubitemid 47530570)
14. Bozkurt D, Kircelli F, Asci G, Duman S, Dheir H, Toz H, Ozkaya M, Akcicek A, Ok E: Low level of 1,25-dihydroxy vitamin D is associated with mortality in prevalent hemodialysis patients. J Am Soc Nephrol 2008; 19: 296A.
15. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456. (Pubitemid 36910023)
16. Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, Inaba M, Fukumoto S, Ishimura E, Miki T, Tabata T, Nishizawa Y: Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004; 19: 179-184. (Pubitemid 38072630)
17. Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B: Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008; 19: 1613-1619.
18. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K: Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008; 168: 397-403. (Pubitemid 351350586)
19. Inaguma D, Hamaguchi K, NagayaH, Tatematsu M, Suzuki S, Kurata K: The effect of treatment of alfacalcidol on survival in patients with predialysis chronic kidney disease. J Am Soc Nephrol 2008; 19: 297A.
20. Dukas L, Bischoff HA, Lindpaintner LS, Schacht E, Birkner-Binder D, Damm TN, Thalmann B, Stähelin HB: Alfacalcidol reduces the number of fallers in a communitydwelling elderly population with a minimum calcium intake of more than 500 mg daily. J Am Geriatr Soc 2004; 52: 230-236. (Pubitemid 38233485)